IAH 0968
Alternative Names: IAH-0968Latest Information Update: 24 Jul 2024
At a glance
- Originator SUNHO (China) BioPharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Colorectal cancer
- Phase I/II Cholangiocarcinoma; Solid tumours
Most Recent Events
- 17 Jul 2024 SUNHOChinaBioPharmaceutical plans a phase II/III trial for Solid tumours, Gastric cancer and Colorectal cancer (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Inoperable/unresectable, Second-line therapy or greater, First-line therapy) in China (Parenteral) (NCT06504732)
- 02 Jun 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT04934514)
- 02 Jun 2023 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT04934514)